NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 421
(Total Views: 229)
Posted On: 03/24/2023 5:03:46 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in. Moreover, the further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties,” reads a recent article that contains excerpts from a LabioTech writeup. “Lexaria ticks all these boxes. Its unique technology – DehydraTECH – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023… Lastly, and perhaps most importantly, Lexaria has substantially invested in research and development (‘R&D’), an aspect of its operations that is 100% within its control. According to CEO Chris Bunka, the company has designed its applied R&D to boost its commercial prospects, and this ‘is paying off in spades,’ as it has, among others, ‘yielded almost entirely positive results.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in. Moreover, the further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties,” reads a recent article that contains excerpts from a LabioTech writeup. “Lexaria ticks all these boxes. Its unique technology – DehydraTECH – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023… Lastly, and perhaps most importantly, Lexaria has substantially invested in research and development (‘R&D’), an aspect of its operations that is 100% within its control. According to CEO Chris Bunka, the company has designed its applied R&D to boost its commercial prospects, and this ‘is paying off in spades,’ as it has, among others, ‘yielded almost entirely positive results.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)